Opioids Market to Reach $31.9 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 1563. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Opioids Industry" - https://www.reportlinker.com/p06042706/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

• Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

• Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

• Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

• Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

• Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Opioids Market to Reach $31.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Opioids estimated at US$25.4 Billion in the year 2020, is projected to reach a revised size of US$31.9 Billion by 2027, growing at aCAGR of 3.3% over the period 2020-2027. Immediate-Release/Short-Acting Opioid, one of the segments analyzed in the report, is projected to record 2.5% CAGR and reach US$16 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Extended-Release/Long-Acting Opioid segment is readjusted to a revised 4.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $6.9 Billion, While China is Forecast to Grow at 5.9% CAGR
- The Opioids market in the U.S. is estimated at US$6.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

- Select Competitors (Total 31 Featured) -

• Egalet Corporation

• Janssen Pharmaceuticals, Inc.

• Pfizer, Inc.

• Purdue Pharma LP

• Sanofi

• Sun Pharmaceutical Industries Ltd.

• West-Ward Pharmaceuticals Corporation

Read the full report: https://www.reportlinker.com/p06042706/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Opioids by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Opioids by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Opioids by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for
Immediate-Release/Short-Acting Opioid by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for
Immediate-Release/Short-Acting Opioid by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for
Immediate-Release/Short-Acting Opioid by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for
Extended-Release/Long-Acting Opioid by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Extended-Release/Long-Acting
Opioid by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for
Extended-Release/Long-Acting Opioid by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Pain Relief by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Pain Relief by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Pain Relief by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Anesthesia by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Anesthesia by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Anesthesia by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Cough Suppression
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Cough Suppression by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Cough Suppression by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Diarrhea
Suppression by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Diarrhea Suppression by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Diarrhea Suppression by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Deaddiction by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Deaddiction by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Deaddiction by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 26: USA Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 27: USA 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 28: USA Current & Future Analysis for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 32: Canada Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 33: Canada 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 34: Canada Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 38: Japan Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 39: Japan 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 40: Japan Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

CHINA
Table 43: China Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 44: China Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 45: China 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 46: China Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

EUROPE
Table 49: Europe Current & Future Analysis for Opioids by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Opioids by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Opioids by Geographic
Region - Percentage Breakdown of Value Sales for France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 53: Europe Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 54: Europe 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 55: Europe Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

FRANCE
Table 58: France Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 59: France Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 60: France 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 61: France Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

GERMANY
Table 64: Germany Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 65: Germany Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 66: Germany 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 67: Germany Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

ITALY
Table 70: Italy Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 71: Italy Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 72: Italy 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 73: Italy Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 76: UK Current & Future Analysis for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 77: UK Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 78: UK 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 79: UK Current & Future Analysis for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: UK Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

SPAIN
Table 82: Spain Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 83: Spain Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Spain 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 85: Spain Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: Spain Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 87: Spain 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

RUSSIA
Table 88: Russia Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 89: Russia Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 90: Russia 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 91: Russia Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Russia Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 93: Russia 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 94: Rest of Europe Current & Future Analysis for Opioids
by Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 95: Rest of Europe Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Opioids by
Segment - Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 97: Rest of Europe Current & Future Analysis for Opioids
by End-Use - Pain Relief, Anesthesia, Cough Suppression,
Diarrhea Suppression and Deaddiction - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 98: Rest of Europe Historic Review for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 99: Rest of Europe 15-Year Perspective for Opioids by
End-Use - Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 100: Asia-Pacific Current & Future Analysis for Opioids
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Opioids by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Opioids by
Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2012, 2020 & 2027

Table 103: Asia-Pacific Current & Future Analysis for Opioids
by Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 104: Asia-Pacific Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 105: Asia-Pacific 15-Year Perspective for Opioids by
Segment - Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 106: Asia-Pacific Current & Future Analysis for Opioids
by End-Use - Pain Relief, Anesthesia, Cough Suppression,
Diarrhea Suppression and Deaddiction - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 107: Asia-Pacific Historic Review for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 108: Asia-Pacific 15-Year Perspective for Opioids by
End-Use - Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

AUSTRALIA
Table 109: Australia Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 110: Australia Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 111: Australia 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 112: Australia Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 113: Australia Historic Review for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 114: Australia 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

INDIA
Table 115: India Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 116: India Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 117: India 15-Year Perspective for Opioids by Segment -
Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 118: India Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: India Historic Review for Opioids by End-Use - Pain
Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 120: India 15-Year Perspective for Opioids by End-Use -
Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

SOUTH KOREA
Table 121: South Korea Current & Future Analysis for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 122: South Korea Historic Review for Opioids by Segment -
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 123: South Korea 15-Year Perspective for Opioids by
Segment - Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 124: South Korea Current & Future Analysis for Opioids by
End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 125: South Korea Historic Review for Opioids by End-Use -
Pain Relief, Anesthesia, Cough Suppression, Diarrhea
Suppression and Deaddiction Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 126: South Korea 15-Year Perspective for Opioids by
End-Use - Percentage Breakdown of Value Sales for Pain Relief,
Anesthesia, Cough Suppression, Diarrhea Suppression and
Deaddiction for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 127: Rest of Asia-Pacific Current & Future Analysis for
Opioids by Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 128: Rest of Asia-Pacific Historic Review for Opioids by
Segment - Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 129: Rest of Asia-Pacific 15-Year Perspective for Opioids
by Segment - Percentage Breakdown of Value Sales for
Immediate-Release/Short-Acting Opioid and
Extended-Release/Long-Acting Opioid for the Years 2012, 2020 &
2027

Table 130: Rest of Asia-Pacific Current & Future Analysis for
Opioids by End-Use - Pain Relief, Anesthesia, Cough
Suppression, Diarrhea Suppression and Deaddiction - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06042706/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001